Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MA Current Enrollment Would Be Cut By 35% With Competitive Bidding – CBO

Executive Summary

Enrollment in the Medicare Advantage program would decline to about 6.9 million individuals in 10 years if plan sponsors are required to participate in a competitive bidding process that would effectively cut payment rates, based on recent estimates from the Congressional Budget Office

You may also be interested in...



MA Fight Begins: Obama Turns Free Market Rhetoric Back Against Plans

UnitedHealth, Humana and the rest of the managed care industry have begun their defense against the Obama administration's cutbacks in Medicare Advantage payment rates, with 9.1 million Medicare beneficiaries currently receiving coverage through their plans

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051096

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel